Literature DB >> 23215813

Metabolism of the antituberculosis drug ethionamide.

Nuno Vale1, Paula Gomes, Hélder A Santos.   

Abstract

Ethionamide (ETH) is an important second-line antituberculosis drug used for the treatment of patients infected with multidrug-resistant Mycobacterium. Although ETH is a structural analogue of isoniazid (INH), both are pro-drugs that need to be activated by mycobacterial enzymes to exert their antimicrobial activity. ETH mechanism of action is thought to be identical to INH although the pathway of activation is distinct from that of INH. ETH is activated by an EthA enzyme, leading to the formation of an Soxide metabolite that has considerably better activity than the parent drug. This review comprehensively examines the aspects related with the metabolism of ETH since its discovery up to today.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23215813

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  6 in total

1.  Genotypic Analysis of Genes Associated with Independent Resistance and Cross-Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis Clinical Isolates.

Authors:  Johana Rueda; Teresa Realpe; Gloria Isabel Mejia; Elsa Zapata; Juan Carlos Rozo; Beatriz Eugenia Ferro; Jaime Robledo
Journal:  Antimicrob Agents Chemother       Date:  2015-09-14       Impact factor: 5.191

2.  EthA/R-Independent Killing of Mycobacterium tuberculosis by Ethionamide.

Authors:  Michelle L T Ang; Siti Z Zainul Rahim; Paola Florez de Sessions; Wenwei Lin; Vanessa Koh; Kevin Pethe; Martin L Hibberd; Sylvie Alonso
Journal:  Front Microbiol       Date:  2017-04-25       Impact factor: 5.640

Review 3.  MDR Tuberculosis Treatment.

Authors:  Juan Espinosa-Pereiro; Adrian Sánchez-Montalvá; Maria Luisa Aznar; Maria Espiau
Journal:  Medicina (Kaunas)       Date:  2022-01-26       Impact factor: 2.430

Review 4.  Antimycobacterial Metabolism: Illuminating Mycobacterium tuberculosis Biology and Drug Discovery.

Authors:  Divya Awasthi; Joel S Freundlich
Journal:  Trends Microbiol       Date:  2017-06-13       Impact factor: 17.079

5.  Cyclic di-GMP regulates Mycobacterium tuberculosis resistance to ethionamide.

Authors:  Hai-Nan Zhang; Zhao-Wei Xu; He-Wei Jiang; Fan-Lin Wu; Xiang He; Yin Liu; Shu-Juan Guo; Yang Li; Li-Jun Bi; Jiao-Yu Deng; Xian-En Zhang; Sheng-Ce Tao
Journal:  Sci Rep       Date:  2017-07-19       Impact factor: 4.379

6.  Ethionamide Preconditioning Enhances the Proliferation and Migration of Human Wharton's Jelly-Derived Mesenchymal Stem Cells.

Authors:  Na-Hee Lee; Su Hyeon Myeong; Hyo Jin Son; Jung Won Hwang; Na Kyung Lee; Jong Wook Chang; Duk L Na
Journal:  Int J Mol Sci       Date:  2020-09-23       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.